EA201791688A8 - Применение prg4 в качестве противовоспалительного средства - Google Patents

Применение prg4 в качестве противовоспалительного средства

Info

Publication number
EA201791688A8
EA201791688A8 EA201791688A EA201791688A EA201791688A8 EA 201791688 A8 EA201791688 A8 EA 201791688A8 EA 201791688 A EA201791688 A EA 201791688A EA 201791688 A EA201791688 A EA 201791688A EA 201791688 A8 EA201791688 A8 EA 201791688A8
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory
prg4
tool
application
pro
Prior art date
Application number
EA201791688A
Other languages
English (en)
Other versions
EA201791688A1 (ru
EA036291B1 (ru
Inventor
Грегори Д. Джей
Беджамин Д. Салливан
Таннин Эвери Шмидт
Халед Эльсаид
Эдвард Р. Труитт
Роман Краветц
Джоанна Шмидингер-Ходобска
Адам Ходобски
Джавед Фарид
Original Assignee
ЛУБРИС ЭлЭлСи
Род Айленд Хоспитал, Э Лайф Спэн Партнер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЛУБРИС ЭлЭлСи, Род Айленд Хоспитал, Э Лайф Спэн Партнер filed Critical ЛУБРИС ЭлЭлСи
Publication of EA201791688A1 publication Critical patent/EA201791688A1/ru
Publication of EA201791688A8 publication Critical patent/EA201791688A8/ru
Publication of EA036291B1 publication Critical patent/EA036291B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

В настоящем описании описаны способы применения гликопротеина PRG4, также известного как лубрицин, для снижения, ингибирования или подавления провоспалительных каскадов у пациентов, имеющих риск или страдающих от воспалительного ответа или симптома аллергии посредством антагонизма CD44, регуляции продукции провоспалительных цитокинов, ингибирования транслокации NF-κВ и/или облегчения удаления индуцирующего воспаление клеточного или матриксного дебриса или аллергенов.
EA201791688A 2015-01-26 2016-01-26 Применение prg4 в качестве противовоспалительного средства EA036291B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107799P 2015-01-26 2015-01-26
US201562273059P 2015-12-30 2015-12-30
PCT/US2016/014952 WO2016123123A1 (en) 2015-01-26 2016-01-26 Use of prg4 as an anti-inflammatory agent

Publications (3)

Publication Number Publication Date
EA201791688A1 EA201791688A1 (ru) 2018-01-31
EA201791688A8 true EA201791688A8 (ru) 2018-05-31
EA036291B1 EA036291B1 (ru) 2020-10-22

Family

ID=55361962

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791688A EA036291B1 (ru) 2015-01-26 2016-01-26 Применение prg4 в качестве противовоспалительного средства

Country Status (21)

Country Link
US (2) US10967048B2 (ru)
EP (2) EP3250221B1 (ru)
JP (2) JP6758299B2 (ru)
KR (1) KR20170123619A (ru)
CN (2) CN113908257A (ru)
AU (2) AU2016211694B2 (ru)
BR (1) BR112017015310A8 (ru)
CA (1) CA2972817A1 (ru)
CL (2) CL2017001893A1 (ru)
EA (1) EA036291B1 (ru)
ES (1) ES2808199T3 (ru)
HK (1) HK1247834A1 (ru)
IL (2) IL253596B (ru)
MA (1) MA53108A (ru)
MX (1) MX2017009723A (ru)
PH (1) PH12017501323A1 (ru)
RU (1) RU2017129880A (ru)
SG (2) SG10201809947UA (ru)
TN (1) TN2017000270A1 (ru)
WO (1) WO2016123123A1 (ru)
ZA (1) ZA201705378B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
JP6571101B2 (ja) 2013-11-26 2019-09-04 ルブリス，エルエルシー． 細胞間相互作用を阻害するための組成物及び方法
CA2972817A1 (en) 2015-01-26 2016-08-04 Lubris Llc Use of prg4 as an anti-inflammatory agent
US11089832B2 (en) 2015-05-01 2021-08-17 Gentex Corporation Helmet impact attenuation article
EP3300482B1 (en) 2015-05-19 2021-07-14 Lubris LLC Use of prg4 to improve dynamic visual acuity and higher order aberrations
CN106215170A (zh) * 2016-08-23 2016-12-14 重庆医科大学 白细胞介素36α在制备治疗、诊断或预防脓毒症药物中的用途
WO2018217921A1 (en) 2017-05-23 2018-11-29 Harmony Development Group, Inc. Tethered implantable device having a vortical intracardiac velocity adjusting balloon
US10940002B2 (en) 2017-06-28 2021-03-09 Harmony Development Group, Inc. Force transducting inflatable implant system including a dual force annular transduction implant
WO2019173385A1 (en) 2018-03-05 2019-09-12 Harmony Development Group, Inc. A force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
WO2019246522A1 (en) * 2018-06-21 2019-12-26 Lubris Llc Lubricin for use in wound healing
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
CN109620952A (zh) * 2019-01-04 2019-04-16 北京中台恒基生物技术有限公司 一种肿瘤疫苗及其制备方法
US20220127318A1 (en) * 2019-01-15 2022-04-28 Cornell University Recombinant lubricins, and compositions and methods for using the same
WO2020232148A1 (en) * 2019-05-13 2020-11-19 The Johns Hopkins University Macrophage diversity in regenerative, fibrotic biomaterial environments
WO2020247440A1 (en) * 2019-06-03 2020-12-10 Lubris Llc Use of prg4 to treat cancer
WO2022010996A1 (en) * 2020-07-07 2022-01-13 University Of Connecticut Method and composition for reducing or preventing bone resorption
IT202000022636A1 (it) * 2020-09-25 2022-03-25 Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma”
CN114184792B (zh) * 2021-11-17 2024-05-28 中国人民解放军总医院第二医学中心 冠心病标志物il-29及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US20020006665A1 (en) 2000-04-05 2002-01-17 D'elia John Ketogulonigenium endogenous plasmids
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
US7642236B2 (en) * 2003-08-14 2010-01-05 Wyeth Recombinant lubricin molecules and uses thereof
WO2005102363A2 (en) 2004-04-20 2005-11-03 Mucosal Therapeutics Llc Methods of promoting cartilage healing or cartilage integration
AU2005267012A1 (en) * 2004-07-23 2006-02-02 Mucosal Therapeutics Llc Compositions and methods for viscosupplementation
WO2006060473A2 (en) 2004-12-03 2006-06-08 Mucosal Therapeutics Llc Methods of treatment of injured or diseased joints with lubricin compositions
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
CN101077887A (zh) * 2006-05-23 2007-11-28 中国医学科学院血液学研究所 人促造血细胞增殖的细胞因子及其制备方法和用途
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US20090191287A1 (en) 2008-01-29 2009-07-30 Johnson W Dudley Mitigation of Inflammation-Related Injuries
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
ES2633792T3 (es) 2008-05-07 2017-09-25 The Regents Of The University Of California Reposición y enriquecimiento terapéuticos de la lubricación de la superficie ocular
EP2381957B1 (en) * 2009-01-13 2015-01-07 Lubris LLC Therapeutic modulation of vaginal epithelium boundary lubrication
JP2012527485A (ja) * 2009-05-22 2012-11-08 ルブリス，エルエルシー． Ｐｒｇ４及びその治療調節作用の応用及び使用
WO2011019963A2 (en) * 2009-08-13 2011-02-17 Singularis, Inc. Prg4 treatment for interstitial cystitis
ES2627103T3 (es) 2010-01-19 2017-07-26 Lubris Llc Composiciones de cuidado bucal y métodos
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
DK2948553T3 (da) * 2013-01-25 2020-06-29 Baylor College Medicine Hjælper-afhængigt afgivelses- og ekspressionssystem til adenoviral genterapi
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
JP6571101B2 (ja) 2013-11-26 2019-09-04 ルブリス，エルエルシー． 細胞間相互作用を阻害するための組成物及び方法
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
CA2972817A1 (en) 2015-01-26 2016-08-04 Lubris Llc Use of prg4 as an anti-inflammatory agent
EP3300482B1 (en) 2015-05-19 2021-07-14 Lubris LLC Use of prg4 to improve dynamic visual acuity and higher order aberrations
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
EA201791688A1 (ru) 2018-01-31
CA2972817A1 (en) 2016-08-04
KR20170123619A (ko) 2017-11-08
SG10201809947UA (en) 2018-12-28
BR112017015310A2 (pt) 2018-01-16
HK1247834A1 (zh) 2018-10-05
TN2017000270A1 (en) 2018-10-19
IL253596B (en) 2021-08-31
SG11201705636SA (en) 2017-08-30
EP3718559A1 (en) 2020-10-07
JP2018505867A (ja) 2018-03-01
ZA201705378B (en) 2020-11-25
CN107847556A (zh) 2018-03-27
ES2808199T3 (es) 2021-02-25
US20210299214A1 (en) 2021-09-30
MX2017009723A (es) 2018-08-15
US11717557B2 (en) 2023-08-08
AU2016211694B2 (en) 2021-11-11
MA53108A (fr) 2021-05-12
RU2017129880A (ru) 2019-03-04
EA036291B1 (ru) 2020-10-22
EP3250221B1 (en) 2020-05-27
EP3250221A1 (en) 2017-12-06
US10967048B2 (en) 2021-04-06
JP7212653B2 (ja) 2023-01-25
PH12017501323A1 (en) 2018-02-05
WO2016123123A1 (en) 2016-08-04
CL2018003302A1 (es) 2019-01-04
BR112017015310A8 (pt) 2021-02-23
AU2022200812A1 (en) 2022-02-24
AU2016211694A1 (en) 2017-08-31
US20180015141A1 (en) 2018-01-18
JP6758299B2 (ja) 2020-09-23
CL2017001893A1 (es) 2018-06-15
IL285553A (en) 2021-09-30
CN113908257A (zh) 2022-01-11
JP2020189878A (ja) 2020-11-26
CN107847556B (zh) 2021-09-24
IL253596A0 (en) 2017-09-28
RU2017129880A3 (ru) 2019-08-22

Similar Documents

Publication Publication Date Title
EA201791688A8 (ru) Применение prg4 в качестве противовоспалительного средства
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
HUE059752T2 (hu) A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
SG11202103191QA (en) Benzimidazole derivative for use in the treatment of inflammatory disorders
EP4356962A3 (en) Selective il-6-trans-signalling inhibitor compositions
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
EA201791937A1 (ru) Противовоспалительные полипептиды
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale
EA201792603A1 (ru) Ангиогенез с использованием стимулированных плацентарных стволовых клеток
IT201600122310A1 (it) Composizione per uso nella terapia di alterazioni dell'intestino
ITUA20163037A1 (it) Formulazioni per uso nel trattamento o prevenzione di disturbi urologici
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases
DOP2015000290A (es) Benzoxazoles sustituidos